The peptide blend CJC-1295/Ipamorelin is a combination of the peptides CJC-1295 and Ipamorelin.

How CJC-1295 and Ipamorelin Work Together

CJC-1295 and Ipamorelin have been combined as a peptide blend because they share similar functional properties that allow them to work well together.

CJC-1295, when introduced to animal test subjects as part of a scientific study, affects the number of secreting cells and the amount of secretions they are able to express. It is chiefly responsible for providing a sense of homeostasis in relation to growth regulation. The introduction of this peptide allows for an increase in activity relating to a cell’s ability to express secretions as well as the amount of expressions that they are able to secrete. CJC-1295 is primarily able to perform this function because of its capability to extend its half-life. Scientific study based an animal test subjects have determined that this half-life can expand from less than seven minutes to more than seven days. Because of this lengthening, the functionality of the peptide in turn allows for a longer period of what the secretions can do within an animal test subject’s body. In this case, it is tied to the ability to synthesize proteins at an accelerated rate, which would then lead to more efficient bodily functions related to several endocrine system-related processes, including:

- Quicker rate of injury recovery
- Increase in bone density
- Stronger immune system
- More efficient growth of muscular tissue

The secretagogue agonist Ipamorelin also stimulates secretions relating to growth. Specifically, it stimulates secretions produced by the pituitary gland; the pea-sized gland located at the base of the brain that is responsible for controlling all of an animal test subject’s endocrine-based functionalities. It’s functionality is similar to that of the peptide GHRP-6, in that it suppresses the secretion of somatostatin, which is a peptide that blocks the release of the very secretions that Ipamorelin promotes. However, there is one key difference between Ipamorelin and the other peptide. Unlike GHRP-6, which inadvertently promotes an increase in the production of the hunger-stimulating peptide ghrelin, Ipamorelin has no such by-product attached to its expression, thus allowing animal test subjects to retain a proper level of homeostasis in relation to hunger levels.
Much like CJC-1295, the secretions that Ipamorelin does promote do specifically tie into the secretions relating to growth. Scientific study based on animal test subjects has determined that the peptide’s facilities do enable an efficient, more accelerated process on several key functions tying into the endocrine system’s control and regulation of growth and repair. These include:

- Strength of bone mass and connective tissue
- More efficient fat loss
- Joint rejuvenation and strengthening

In addition to the functions that Ipamorelin does, the functions that don’t occur as a result of the peptide’s presence are also worthy of note. For example, Ipamorelin does not significantly elevate the production levels of cortisol, which is a secretion that elevates the level of blood sugar in animal test subjects. The lack of increase allows an animal test subject’s body to retain a level of homeostasis when it comes to blood sugar. Also, Ipamorelin does not significantly boost the production of prolactin; the secretion that is vital in regulating the immune system of animal test subjects. This is key to note because this particular peptide plays a significant role in the lactation process amongst female test subjects, thus allowing that delicate process to maintain a level of homeostasis.

Minimal Side Effects

When blended together, CJC-1295 and Ipamorelin forge a strong alliance in terms of promoting secretions relating to the growth and repair of several endocrine system-related functions. What’s more, scientific study based on animal test subjects has determined that side effects that have been associated to the blend have been mild in nature. The side effects that have been associated with the CJC-1295/Ipamorelin blend chiefly consist of headaches, light-headedness, fatigue, water retention, and a temporary numbness of the extremities.

For Scientific Use Only

It should be noted that, even though there have been several scientific studies on animal test subjects that have yielded potentially positive results in relation to the blend of CJC-1295 and Ipamorelin, the peptide combination is still very much in the medical research stage. Furthermore, it should be noted that any findings positive and negative relating to the blend is still the product on research conducted on animal test subjects within a strictly controlled environment. Because of this, it needs to be stressed that any research or study relating to the CJC-1295/Ipamorelin blend should only be contained to an environment such as a laboratory or a clinical research facility.